First Patients Dosed in Three Trials Assessing Dato-DXd-Based Regimens in Lung Cancer
The first patients with locally advanced or metastatic nonsquamous non-small cell lung cancer have been dosed in three phase 3 trials that will be assessing the safety and efficacy of datopotamab deruxtecan (Dato-DXd)-based combinations. The three phase 3 …